Fig. 2: The therapeutic efficacy of cDC1-based anti-cancer vaccination is superior to cDC2s. | Nature Communications

Fig. 2: The therapeutic efficacy of cDC1-based anti-cancer vaccination is superior to cDC2s.

From: Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

Fig. 2

a Experimental overview for (b, c): 4 × 105 B16-OVA cells were intravenously (i.v.) injected into naive mice. On day 3, the mice received an i.v. injection of 106 B16-OVA-TCL+CpG-pulsed splenic cDC1s or cDC2s or PBS as control. Lungs were harvested on day 21 for analysis. b Lung area covered by tumor nodules normalized to untreated control lungs is shown (n = 12 [control], 14 [cDC1], 8 [cDC2] biological replicates/group from 2 independent experiments). c Representative image of 3 lung lobes harboring tumor nodules. d Experimental overview for (e, f): 5 × 105 MC38 cells were subcutaneously (s.c.) injected in the right flank of naive mice. On day 3 and 8, the mice received intradermal (i.d.) injections of 106 MC38-TCL+CpG-pulsed splenic cDC1s or cDC2s or PBS (control). e Tumor growth and (f) humane endpoint are shown (n = 27 [control], 12 [cDC1], 14 [cDC2] biological replicates/group from 3 independent experiments). Data are presented as mean ± SEM (dots represent individual data points). Statistical analysis by one-way ANOVA and Tukey post-hoc test (b), two-way ANOVA (e) and Mantel-Cox test (f). Source data are provided as Source Data file.

Back to article page